文献速递前列腺癌

HOXB13表达与前列腺癌根治术后转移进展相关

Somatic HOXB13 Expression Correlates with Metastatic Progression in Men with Localized Prostate Cancer Following Radical Prostatectomy.
PubMed 文献 · Eur Urol Oncol · 2020-06-12

基于两个回顾性前列腺切除术队列(Mayo Clinic n=780;JHMI n=355)和一个前瞻性基因组登记(n=5239),分析HOXB13 mRNA表达与术后无转移生存的关系。结果显示HOXB13最高四分位与较低四分位相比无转移生存更差,且HOXB13高表达合并MEIS1/2低表达时风险进一步升高。

要点

  • HOXB13高表达与根治术后无转移生存更差相关。
  • HOXB13高表达合并MEIS1或MEIS2低表达者转移风险更高。
  • 该表型可能提示对雄激素抑制更敏感。

核心结论

  • 原发前列腺癌HOXB13表达升高者根治术后转移倾向增加,尤其合并MEIS1/2低表达时。

研究设计与样本

  • 回顾性分析两个前列腺切除术队列(Mayo Clinic n=780;JHMI n=355)及一个前瞻性基因组登记(n=5239)。
  • 采用多变量Cox回归分析无转移生存(MFS)。

主要发现

  • HOXB13表达随肿瘤分级升高而增加,并与基因组特征提示的高转移潜能相关。
  • HOXB13最高四分位与最低四分位相比MFS更差:Mayo Clinic调整风险比(AHR)1.46,95%CI 1.03-2.06;JHMI AHR 1.80,95%CI 1.02-3.19。
  • HOXB13高表达合并MEIS1低表达AHR 2.03(95%CI 1.54-2.66),合并MEIS2低表达AHR 1.73(95%CI 1.33-2.26),均提示MFS更差。
  • HOXB13高表达合并MEIS1/2低表达与雄激素受体介导基因高表达相关。

临床怎么用

  • HOXB13高表达尤其合并MEIS1/2低表达的前列腺癌术后患者可能需更密切监测转移。
  • 该分子特征提示对雄激素抑制可能更敏感,但需进一步验证。

局限性

  • 研究为回顾性设计,未测量变量可能导致偏倚。

以上解读依据论文摘要(全文未开放获取或许可不允许翻译转载)。

原文

BACKGROUND: Homeobox B13 (HOXB13) expression regulates normal prostate development and mutations are associated with prostate cancer (PCa) formation. OBJECTIVE: To assess the role of HOXB13 mRNA expression in PCa progression following radical prostatectomy. DESIGN, SETTING, AND PARTICIPANTS: Genome-wide expression profiles were queried from two retrospective prostatectomy cohorts with follow-up data (Mayo Clinic, n=780; Johns Hopkins Medical Institute [JHMI], n=355), and a prospective genomic registry (n=5239). OUTCOME MEASUREMENTS AND STATISTICAL ANALYSIS: Multivariable Cox regressions were used to analyze metastasis-free survival (MFS). RESULTS AND LIMITATIONS: HOXB13 expression in primary PCa increased with increasing tumor grade and with high metastatic potential based on a genomic signature. The highest quartile of HOXB13 expression was associated with worse MFS compared with the lowest quartile (Mayo Clinic: adjusted hazard ratio [AHR] 1.46, 95% confidence interval [CI] 1.03-2.06, and JHMI: AHR 1.80, 95% CI 1.02-3.19). The combinations of high HOXB13 expression and low expression of its binding partner, MEIS1 (AHR 2.03, 95% CI 1.54-2.66) or MEIS2 (AHR 1.73, 95% CI 1.33-2.26), portended worse MFS. Additionally, high HOXB13 expression in combination with low MEIS1/2 expression correlated with high expression of androgen receptor-mediated genes. The retrospective nature of this study subjects the findings to a bias due to unmeasured variables. CONCLUSIONS: Primary PCa tumors with increased HOXB13 expression have an increased propensity for metastases following prostatectomy, particularly in the setting of low MEIS1/2 expression. High androgen receptor output may account for worse outcomes for these tumors and suggests heightened sensitivity to androgen suppression. PATIENT SUMMARY: Using genomic data from a large number of prostate cancer (PCa) tumors, we found that increased expression of homeobox B13 (HOXB13), a gene related to normal prostate development, was associated with worse outcomes following surgery for PCa. A biomarker signature suggests that these tumors would be more susceptible to androgen suppression, a common treatment for PCa. Take Home Messagece:: In multiple large cohorts, prostate cancer tumors with high homeobox B13 (HOXB13) expression and low expression of its binding partner MEIS1/2 were enriched with high androgen receptor output and had an increased propensity for metastases following surgery.

来源:Eur Urol Oncol,查看原文。版权归原作者所有。

引用

  1. Weiner AB, Faisal FA, Davicioni E, et al. Somatic HOXB13 Expression Correlates with Metastatic Progression in Men with Localized Prostate Cancer Following Radical Prostatectomy. Eur Urol Oncol. 2020. PMID: 32540218. doi:10.1016/j.euo.2020.05.001

供执业医师工作参考,不替代临床判断;数值与分级以指南原文为准。